infect
particularli
pneumonia
patient
intens
care
unit
icu
common
associ
signific
mortal
alberti
et
al
heyland
et
al
patient
differ
type
lower
respiratori
tract
infect
may
manag
icu
includ
sever
communityacquir
pneumonia
cap
hospitalacquir
pneumonia
hap
healthcareassoci
pneumonia
hcap
ventilatorassoci
pneumonia
vap
thu
rang
pathogen
may
associ
infect
vast
elsolh
et
al
heyland
et
al
b
reimer
carrol
rello
et
al
icu
much
effort
place
diagnosi
treatment
bacteri
agent
caus
pneumonia
littl
effort
place
detect
manag
viral
agent
except
special
situat
atsidsa
fact
recent
guidelin
suggest
incid
hap
vap
due
virus
low
immunocompet
host
although
outbreak
hap
vap
hcap
due
virus
report
atsidsa
thu
littl
emphasi
place
tri
make
viral
diagnosi
extent
percept
virus
uncommon
set
due
difficulti
detect
agent
clinic
microbiolog
lab
lack
avail
treatment
virus
caus
infect
respiratori
tract
holladay
campbel
howev
develop
molecular
diagnost
techniqu
polymeras
chain
reaction
pcr
particularli
multiplex
detect
multipl
differ
virus
singl
reaction
potenti
provid
new
insight
epidemiolog
manag
patient
pneumonia
icu
set
mahoni
et
al
mani
bronchoalveolar
lavag
bal
specimen
bacterianeg
bal
collect
adult
patient
acut
pneumonia
intens
care
unit
may
posit
respiratori
virus
legoff
et
al
rate
may
even
higher
children
straliotto
et
al
other
suggest
despit
find
respiratori
viru
tracheobronchi
aspir
collect
patient
ventil
hour
nosocomi
viral
vap
like
rare
icu
daubin
et
al
greater
sensit
tradit
laboratori
techniqu
assay
detect
virus
previous
would
miss
thu
help
redefin
spectrum
diseas
contribut
agent
morbid
mortal
patient
icu
tradit
viral
techniqu
cultur
antigen
detect
immunofluoresc
stain
capabl
detect
agent
influenza
virus
b
respiratori
syncyti
viru
parainfluenza
virus
adenoviru
molecular
techniqu
expand
rang
virus
rapidli
detect
laboratori
includ
mani
newli
identifi
agent
human
metapneumoviru
bocaviru
coronavirus
other
mahoni
et
al
molecular
techniqu
may
also
aid
prevent
nosocomi
spread
virus
within
icu
allow
appropri
infect
control
measur
implement
quickli
agent
identifi
molecular
assay
also
subtyp
virus
help
determin
related
strain
epidemiolog
outbreak
investig
although
assay
potenti
reduc
unnecessari
antibiot
use
overal
cost
associ
manag
patient
case
recent
studi
patient
admit
hospit
manag
lower
respiratori
tract
infect
oosterheert
et
al
studi
osterheert
et
al
show
although
use
realtim
pcr
detect
viral
atyp
bacteri
pathogen
patient
lower
respiratori
tract
infect
increas
diagnost
yield
consider
reduc
number
diagnost
procedur
antibiot
use
length
hospit
stay
cost
oosterheert
et
al
like
reflect
fact
clinician
reluct
chang
clinic
manag
base
result
pcr
test
prefer
continu
antibiot
concern
miss
bacteri
agent
increas
use
molecular
diagnost
techniqu
may
actual
result
increas
cost
test
rel
expens
also
posit
result
eg
influenza
viru
may
lead
addit
antivir
agent
oseltamivir
rather
replac
patient
current
antibiot
regimen
base
wellrecogn
associ
coinfect
bacteria
virus
respiratori
tract
de
roux
et
al
shown
improv
clinic
outcom
ad
cost
may
well
worth
studi
use
rapid
less
sensit
test
direct
immunofluoresc
assay
dfa
antigen
detect
assay
diagnosi
respiratori
virus
suggest
test
signific
impact
decisionmak
antibiot
use
overal
cost
barenfang
et
al
bonner
et
al
byington
et
al
sharma
et
al
studi
howev
done
infant
children
emerg
depart
outpati
set
hospit
ward
similar
studi
need
use
newer
multiplex
molecular
assay
icu
set
determin
potenti
benefit
achiev
sicker
complex
patient
popul
anoth
issu
use
multiplex
assay
detect
respiratori
virus
icu
season
agent
studi
look
optim
time
assay
perform
need
take
time
research
clinician
comfort
use
result
assay
modifi
decisionmak
manag
strategi
icu
moment
guidelin
manag
cap
hap
hcap
vap
recommend
routin
use
molecular
techniqu
detect
virus
lack
inform
clinic
util
atsidsa
mandel
et
al
could
chang
well
conduct
studi
demonstr
benefit
assay
icu
set
clinician
educ
regard
use
